Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides, a developer of nanomaterials for viral therapy, has signed a material transfer agreement with a major pharmaceutical company.
Subscribe to our email newsletter
The agreement initially entails evaluation of one of the company’s nanoviricide drug candidates by an independent consultant chosen by the party.
This drug candidate has been designed to eradicate viral infections of the external eye, including those caused by adenovirus and herpes virus. It is the understanding of the parties that, should the testing results be favorable, they will enter into good faith negotiations for a potential long-term, exclusive, worldwide licensing agreement for the development and commercialization of the drug.
The terms of the agreement do not allow the disclosure of the identity of the party or the exact terms of the agreement.
Eugene Seymour, CEO of Nanoviricides, said: “This agreement is the first step towards a potential licensing agreement. It clearly signals that our technology is now attracting serious attention from major pharma companies.”